Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 6/20 | 0.56 |
| ▸ | CYP2E1 | P05181 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | ERN1 | O75460 | 1/20 | 0.38 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.36 |
| ▸ | CDK9 | P50750 | 1/20 | 0.36 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
| ▸ | PIM1 | P11309 | 1/20 | 0.31 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL255443 | 0.85 | CYP2A6 (0.56) | CYP2A6CYP2E1CYP3A4CYP2C9CYP2B6 | |
| SCHEMBL5144216 | 0.73 | CYP2A6 (0.65) | CYP2A6 | |
| SCHEMBL9956377 | 0.72 | CYP2A6 (1.00) | CYP2A6PIM1DAO | |
| SCHEMBL91009 | 0.72 | CYP2A6 (1.00) | CYP2A6PIM1DAO | |
| SCHEMBL29502957 | 0.72 | CYP2A6 (1.00) | CYP2A6PIM1DAO | |
| SCHEMBL126266 | 0.71 | MAPT (0.51) | CYP2A6CYP3A4CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL15971544 | 0.71 | CYP2A6 (0.34) | CYP2A6CYP3A4CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL9241840 | 0.71 | PRKCZ (0.39) | CYP2A6CYP3A4CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL31426263 | 0.71 | PIM1 (0.35) | CYP2A6CYP3A4CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL18660624 | 0.71 | PIM1 (0.35) | CYP2A6CYP3A4CYP2C9CYP2C19CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1804781-A1 | NOVEL CYCLIC AND ACYCLIC PROPENONES FOR TREATING CNS DISORDERS | Merz Pharma GmbH & Co.KGaA (DE) | 2007-07-11 | — | — | EP | claimed |
| WO-2006037996-A1 | NOVEL CYCLIC AND ACYCLIC PROPENONES FOR TREATING CNS DISORDERS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2006-04-13 | — | — | WO | claimed |
| US-8193359-B2 | G-protein coupled receptor agonists | PROSIDION LIMITED (GB) | 2012-06-05 | — | — | US | disclosed |
| EP-1709047-B1 | AZABENZOFURAN SUBSTITUTED THIOUREAS AS INHIBITORS OF VIRAL REPLICATION | ACHILLION PHARMACEUTICALS INC (US) | 2010-09-01 | — | — | EP | disclosed |
| US-20090099227-A1 | G-Protein Coupled Receptor Agonists | PROSIDION LIMITED (GB) | 2009-04-16 | — | — | US | disclosed |
| US-7439374-B2 | Azabenzofuran substituted thioureas; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. (US) | 2008-10-21 | — | — | US | disclosed |
| EP-1838706-A1 | G-PROTEIN COUPLED RECEPTOR AGONISTS | Prosidion Limited (GB) | 2007-10-03 | — | — | EP | disclosed |
| WO-2006067532-A1 | G-PROTEIN COUPLED RECEPTOR AGONISTS | PROSIDION LTD (GB) | 2006-06-29 | — | — | WO | disclosed |
| US-7067515-B2 | Quinuclidines-substituted-multi-cyclic-heteroaryls for the treatment of disease | PFIZER INC. (US) | 2006-06-27 | — | — | US | disclosed |
| EP-1406901-A1 | QUINUCLIDINES-SUBSTITUTED-MULTI-CYCLIC-HETEROARYLS FOR THE TREATMENT OF DISEASE | PHARMACIA & UPJOHN COMPANY (US) | 2004-04-14 | — | — | EP | disclosed |
| US-6531466-B2 | E.g., a 1-aza-10-(1-hydroxyethyl-11-oxo-4-(het-methylene)-tricyclo(7.2 .0.0(3,8))undec-2-ene-2-carboxylate; good activity against grampositive bacteria such as methicillin-resistant Staphylococcus aureus and epidermidis | GLAXOSMITHKLINE SPA (IT) | 2003-03-11 | — | — | US | disclosed |
| US-20030045540-A1 | Quinuclidines-substituted-multi-cyclic-heteroaryls for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-03-06 | — | — | US | disclosed |
| EP-0937078-B1 | TRICYCLIC CARBAPENEM COMPOUNDS | GLAXOSMITHKLINE SPA (IT) | 2003-02-12 | — | — | EP | disclosed |
| WO-2002100857-A1 | QUINUCLIDINES-SUBSTITUTED-MULTI-CYCLIC-HETEROARYLS FOR THE TREATMENT OF DISEASE | PHARMACIA & UPJOHN COMPANY (US) | 2002-12-19 | — | — | WO | disclosed |
| US-20010047094-A1 | Tricyclic carbapenem compounds | GLAXO WELLCOME SPA | 2001-11-29 | — | — | US | disclosed |
| EP-0937078-A1 | TRICYCLIC CARBAPENEM COMPOUNDS | GLAXO WELLCOME S.p.A. (IT) | 1999-08-25 | — | — | EP | disclosed |
| WO-1998021210-A1 | TRICYCLIC CARBAPENEM COMPOUNDS | GLAXO WELLCOME S.P.A. (IT) | 1998-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010047094-A1 | Tricyclic carbapenem compounds | OXA1L, GNE, MGAM | CYP2A6 270/4885CYP2E1 190/4885CYP3A4 82/4885 |
| US-20030045540-A1 | Quinuclidines-substituted-multi-cyclic-heteroaryls for the treatment of disease | NQO2, SLC10A1, CYP7A1 | CYP2A6 139/4885CYP2E1 290/4885CYP3A4 328/4885 |
| US-20090099227-A1 | G-Protein Coupled Receptor Agonists | GPR119, GPR65, GPR84 | CYP2A6 770/4885CYP2E1 677/4885CYP3A4 1117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.